129-Men1^tm1Zqw/Orl

Status	Available to order
EMMA ID	EM:01386
International strain name	129-Men1^tm1Zqw/Orl
Alternative name	Men1+/T(argeted)91C
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Men1^tm1Zqw
Gene/Transgene symbol	Men1

Information from provider

Provider	Philippe Bertolino
Provider affiliation	Laboratoire Génétique Moléculaire, Signalisation et Cancer, CNRS, UMR5201, Universté Claude Bern
Genetic information	The Men1 gene was disrupted by the insertion of a floxed neo/TK cassette in intron 2 and of another loxP site in intron 3. The targeted allele thus obtained is not functional in mice. No detectable Men1 transcript and protein in Men1 null mouse tissues.
Phenotypic information	The Men1 null embryos are lethal at E11.5 to E13.5, with neural tube disclosure, and abnormalities in liver and heart development. The heterozygous Men1 mice develop hyperplastic lesions at 8 months and multiple endocrine tumours starting from 12 months.
Breeding history	This strain is always maintained, even currently, by inbred cross (+/targeted X +/targeted), and has never been backcrossed or outcrossed.
References	Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.;Bertolino Philippe, Radovanovic Ivan, Casse Huguette, Aguzzi Adriano, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Mechanisms of development;120;549-60; 12782272 Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.;Bertolino Philippe, Tong Wei-Min, Galendo Dominique, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Molecular endocrinology (Baltimore, Md.);17;1880-92; 12819299

Information from EMMA

Archiving centre	Institut de Transgenose, INTRAGENE, Orléans, France

Disease and phenotype information

MGI allele-associated human disease models

Orphanet associated rare diseases, based on orthologous gene matching

Pituitary gigantism / Orphanet_99725
Familial isolated hyperparathyroidism / Orphanet_99879
Multiple endocrine neoplasia type 1 / Orphanet_652

MGI phenotypes (allele matching)

enlarged pituitary gland / MGI
enlarged adrenal glands / MGI
enlarged testis / MGI
increased adrenal gland tumor incidence / MGI
increased intestinal adenoma incidence / MGI
increased insulinoma incidence / MGI
increased glucagonoma incidence / MGI
increased pancreatic islet cell adenoma incidence / MGI
increased parathyroid adenoma incidence / MGI
thyroid gland hyperplasia / MGI
increased prolactinoma incidence / MGI
enlarged ovary / MGI
increased testis tumor incidence / MGI
increased ovary tumor incidence / MGI
increased adrenal gland adenoma incidence / MGI
increased pancreas tumor incidence / MGI
increased gonad tumor incidence / MGI
increased Leydig cell tumor incidence / MGI
increased gastrointestinal tumor incidence / MGI
increased gland tumor incidence / MGI
increased mammary gland tumor incidence / MGI
increased stomach tumor incidence / MGI
increased thyroid tumor incidence / MGI
increased thyroid carcinoma incidence / MGI
increased pancreatic islet cell carcinoma incidence / MGI
increased pituitary adenohypophysis tumor incidence / MGI
increased adrenal cortical tumor incidence / MGI
increased adrenocortical adenoma incidence / MGI
thin ventricular wall / MGI
trabecula carnea hypoplasia / MGI
delayed hepatic development / MGI
exencephaly / MGI
decreased embryo size / MGI
hemorrhage / MGI
abnormal embryonic tissue morphology / MGI
abnormal neural tube closure / MGI
thin interventricular septum / MGI
lethality throughout fetal growth and development, complete penetrance / MGI

MGI phenotypes (gene matching)

hypoglycemia / MGI
increased circulating calcium level / MGI
decreased circulating phosphate level / MGI
thin ventricular wall / MGI
trabecula carnea hypoplasia / MGI
delayed hepatic development / MGI
abnormal pituitary gland morphology / MGI
enlarged pituitary gland / MGI
enlarged adrenal glands / MGI
exencephaly / MGI
enlarged testis / MGI
Leydig cell hyperplasia / MGI
decreased embryo size / MGI
increased circulating corticosterone level / MGI
pancreas inflammation / MGI
hemorrhage / MGI
abnormal pancreas morphology / MGI
increased tumor incidence / MGI
increased lung adenocarcinoma incidence / MGI
increased adrenal gland tumor incidence / MGI
increased carcinoma incidence / MGI
increased pituitary adenoma incidence / MGI
increased pheochromocytoma incidence / MGI
increased circulating insulin level / MGI
premature death / MGI
abnormal embryonic tissue morphology / MGI
increased intestinal adenoma incidence / MGI
pancreas cysts / MGI
increased insulinoma incidence / MGI
increased glucagonoma incidence / MGI
increased pancreatic islet cell adenoma incidence / MGI
parathyroid gland hyperplasia / MGI
increased parathyroid adenoma incidence / MGI
increased thyroid adenoma incidence / MGI
thyroid gland hyperplasia / MGI
increased prolactinoma incidence / MGI
increased pancreatic beta cell number / MGI
abnormal neural tube closure / MGI
abnormal craniofacial development / MGI
embryonic growth retardation / MGI
enlarged ovary / MGI
abnormal cell differentiation / MGI
homeostasis/metabolism phenotype / MGI
pancreatic islet hyperplasia / MGI
increased testis tumor incidence / MGI
increased ovary tumor incidence / MGI
increased lung tumor incidence / MGI
increased pancreas adenoma incidence / MGI
increased adrenal gland adenoma incidence / MGI
abnormal pancreatic acinar cell morphology / MGI
pancreas necrosis / MGI
increased pancreas tumor incidence / MGI
increased gonad tumor incidence / MGI
increased Leydig cell tumor incidence / MGI
increased gastrointestinal tumor incidence / MGI
increased gland tumor incidence / MGI
increased mammary gland tumor incidence / MGI
increased stomach tumor incidence / MGI
increased thyroid tumor incidence / MGI
increased pituitary gland tumor incidence / MGI
increased parathyroid gland tumor incidence / MGI
increased thyroid carcinoma incidence / MGI
increased pancreatic islet cell carcinoma incidence / MGI
increased pituitary adenohypophysis tumor incidence / MGI
increased adrenal cortical tumor incidence / MGI
increased adrenocortical adenoma incidence / MGI
thin interventricular septum / MGI
embryonic lethality, complete penetrance / MGI
embryonic lethality during organogenesis, complete penetrance / MGI
lethality throughout fetal growth and development, complete penetrance / MGI
thyroid cyst / MGI

Literature references

Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.;Bertolino Philippe, Radovanovic Ivan, Casse Huguette, Aguzzi Adriano, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Mechanisms of development;120;549-60; 12782272
Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.;Bertolino Philippe, Tong Wei-Min, Galendo Dominique, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Molecular endocrinology (Baltimore, Md.);17;1880-92; 12819299

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

129-Men1tm1Zqw/Orl